We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of investment funds sued Allergan, accusing the company of artificially inflating its stock by conspiring with other manufacturers of generic drugs. Read More
A Stanford law professor said the president already has the authority to provide for administration of unapproved drugs to military personnel — a power similar to that proposed for the Department of Defense in pending federal legislation that has raised alarms in Congress. Read More
Continuing education programs could be a useful tool for sponsors charged with providing training and education under a REMS, according to an agency feasibility study. Read More
Writing in an FDA blog post, Commissioner Scott Gottlieb said the agency will broaden the scope of its Expanded Access Navigator tool — an information resource created by the Reagan-Udall Foundation to speed up pre-approval access to drugs. Read More
The FDA published a guidance for industry and its reviewers on the formal CDER and CBER procedures for resolving scientific disputes with sponsors that cannot be settled at the division level, and how to appeal issues to the office or center levels. Read More
The FDA is planning to restructure product review offices in all its centers as it moves toward a team-based approach, Commissioner Scott Gottlieb said Friday at the National Press Club. Read More